Today, 1 in 5 kids will not survive cancer. Since 1978 only 6 drugs have gained approval from the FDA for treatment of childhood cancer. Founded in 2014, Children's Cancer Therapy Development Institute (cc-TDI) has delivered 2 drugs to clinical trial in the first 24 months of operations and is in the midst of 4 more promising research projects! Working as a freestanding non-profit research institution, cc-TDI can act swiftly to achieve results with cost saving measures, speed, purpose and focus to clearly translate into effective treatments for clinical trial. Our research team is exploring and testing state-of-the-art treatment options for the most urgent issues facing children with cancer. By proving these methods in the laboratory, we can deliver smart, hope-filled discoveries to be prioritized in clinical trials for kids. We feel honored to be pioneering Hepatoblastoma Research through the Children’s Cancer Therapy Development Institute with a team of amazingly talented individuals. Addie’s Research is moving forward and we have some remarkable developments to share. Thank you for your unwavering support as our team works tirelessly to save future generations.

Our Hepatoblastoma Team led by 

Dr. Charles Keller, MD

Dr. Keller founded cc-TDI in 2014 after drastic national cuts were made limiting preclinical trials for rare pediatric cancers. His mission of ‘translating scientific discovery into clinical trials by understanding and providing new disease-specific treatments’ became a reality and he has gone full force ever since.  Dr. Keller has authored over 100 scientific publications and is a recognized expert in the biology of childhood sarcomas and the preclinical investigation of childhood cancers. He leads a highly skilled team of specialist to drive Addie’s Hepatoblastoma Research forward.